2008
DOI: 10.1038/ja.2008.98
|View full text |Cite
|
Sign up to set email alerts
|

Macrolactin S, a New Antibacterial Agent with Fab G-inhibitory Activity from Bacillus sp. AT28

Abstract: In the course of screening for FabG inhibitors from microbial sources, a new 24-membered ring lactone named macrolactin S, along with the known compound macrolactin B, has been isolated from the mycelium of liquid fermentation cultures of Bacillus sp. AT28. The structure of macrolactin S was determined on the basis of MS and NMR data. Macrolactin S showed a dosedependent inhibition of Staphylococcus aureus FabG, not inhibiting S. aureus FabI. Also macrolactin S inhibited the growth of S. aureus, Bacillus subti… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
21
0
1

Year Published

2009
2009
2021
2021

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 34 publications
(23 citation statements)
references
References 20 publications
0
21
0
1
Order By: Relevance
“…** fabG: 3-ketoacyl-(acyl-carrier-protein) reductase is a well-known drug target of E. coli, B. subtilis , and S. aureus [40]. …”
Section: Resultsmentioning
confidence: 99%
“…** fabG: 3-ketoacyl-(acyl-carrier-protein) reductase is a well-known drug target of E. coli, B. subtilis , and S. aureus [40]. …”
Section: Resultsmentioning
confidence: 99%
“…[34], the activity of Macrolactin S isolated from Bacillus sp. AT 28 that inhibited the growth of S. aureus , Bacillus subtilis , and Escherichia coli [35], and the antimicrobial activity of Bacillus sp. strain FAS1 isolated from soil was demonstrated on the standard indicator species [36].…”
Section: Discussionmentioning
confidence: 99%
“…However, FabG does not appear to have a rate-controlling role in fatty acid synthesis, making it less desirable as a target. While several natural product FabG inhibitors have been reported [72,73], there has been very little follow through research to validate the selectivity of these inhibitors or develop the compounds further. FabG remains to be validated as a suitable target for drug discovery.…”
Section: Antibiotic Targets In Fatty Acid Metabolismmentioning
confidence: 99%